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Recent experimental and clinical studies have placed new emphasis on the role of angiogenesis in chronic inﬂammatory disease.
Vascular endothelial growth factor (VEGF) and its receptors are the best characterized system in the regulation of rheumatoid
arthritis(RA)byangiogenesis.Furthermore,inadditiontoitsangiogenicrole,VEGFcanactasadirectproinﬂammatorymediator
during the pathogenesis of RA, and protect rheumatoid synoviocytes from apoptosis, which contributes to synovial hyperplasia.
Therefore, the developments of synovial inﬂammation, hyperplasia, and angiogenesis in the joints of RA patients seem to be
regulated by a common cue, namely, VEGF. Agents that target VEGF, such as anti-VEGF antibody and aptamer, have yielded
promising clinical data in patients with cancer or macular degeneration, and in RA patients, pharmacologic modulations targeting
VEGF or its receptor may oﬀer new therapeutic approaches. In this review, the authors integrate current knowledge of VEGF
signaling and information on VEGF antagonists gleaned experimentally and place emphasis on the use of synthetic anti-VEGF
hexapeptide to prevent VEGF interacting with its receptor.
Copyright © 2008 Seung-Ah Yoo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The pathology of rheumatoid arthritis (RA) is characterized
by the proliferation of synovial cells and angiogenesis,
pannus formation. Multiple cell types, including lympho-
cytes, dendritic cells, macrophages, and synovial ﬁbroblasts,
contribute to the chronic inﬂammatory responses of RA,
and comprise a major portion of the invasive pannus [1].
In addition, angiogenesis, the process of new blood vessel
formation, is highly active in RA, particularly during the
earliest stages of the disease [2, 3]. Newly formed vessels
can maintain the chronic inﬂammatory state by transporting
inﬂammatory cells to sites of synovitis, and supply nutrients
and oxygen to the pannus [2, 3]. Angiogenesis is strictly
regulated by many inducers and inhibitors, and a number
of proangiogenic factors have been suggested to be involved
in neovascularization in RA joints. These include acidic and
basic ﬁbroblast growth factors, transforming growth factor
(TGF)-β, angiopoietin, and placenta growth factor (PIGF)
in addition to vascular endothelial growth factor (VEGF)
[2–4].
The ﬁnal goal of RA treatment is complete disease
remission, and not symptomatic relief. At one end of the
spectrum of RA treatment outcomes lie a large group of
patients who do not respond to single disease-modifying
antirheumatic drugs (DMARDs) [5]. Recent clinical trials
have suggested that several biologic agents, such as TNF-α
blockers, rituximab, abatacept, and anakinra, are eﬀective
at retarding joint destruction and at alleviating RA activity
[5, 6]. However, these biologic agents may have serious side
eﬀects, such as predispositions to tuberculosis, lymphoma,
progressive multifocal leukoencephalopathy, and high cost,
which limit their use [7]. It is also a concern that abrupt
stoppages or reductions in these treatments may result in
a relapse of disease activity. Moreover, the pathology of RA
suggests that it is unlikely that a single biologic agent that
targetsaspeciﬁcsubsetofimmunecellsiscapableofeﬀecting
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In this review, we integrate current knowledge con-
cerning how angiogenesis, speciﬁcally VEGF, contributes
to disease exacerbations in RA. In addition, we present
a new therapy for RA based on a synthetic anti-VEGF
hexapeptide that speciﬁcally targets the interaction between
VEGF and its receptor. Prospects for the development of
pharmacologic regulators of placental growth factor, which
is another angiogenic factor implicated in the pathogenesis
of RA, also are discussed.
2. PROINFLAMMATORY AND ANTIAPOPTOTIC ROLES
OF VEGF IN THE PATHOGENESIS OF RA
VEGFisadimericglycoproteinthatinducestheproliferation
and migration of endothelial cells to form new blood vessels,
and which increases vascular permeability. VEGF plays
important roles during wound healing, embryonic develop-
ment, the growths of certain solid tumors, and during ascites
formation [8]. Several recent reports have demonstrated
that VEGF is also implicated in the pathogenesis of RA.
Smoking has been recognized as a signiﬁcant environmental
risk factor in RA [9]. Numerous links have been found
between cigarette smoking and VEGF [10–12]. VEGF in
synovial ﬂuids is signiﬁcantly more increased in RA than in
osteoarthritis [2, 13, 14], and serum levels of VEGF correlate
well with RA disease activity, particularly with swollen joint
counts [13]. VEGF protein and mRNA are expressed by
synovialmacrophagesandsynovialﬁbroblastsinthesynovial
tissues of RA patients, and cultured synovial cells are able to
secrete VEGF under hypoxic conditions or when stimulated
with IL-1, IL-6, IL-17, IL-18, -prostaglandin, or TGF-β,o rb y
CD40 ligation [2–4, 15–17]. Furthermore, VEGF knockout
mice showed reduced pathology and synovial angiogenesis
in antigen-induced models of arthritis [18]. These ﬁndings
strongly suggest that the inhibition of the angiogenic action
of VEGF is likely to suppress rheumatoid inﬂammation.
Angiogenesis and inﬂammation are interdependent pro-
cesses, and inﬂammatory mediators have signiﬁcant eﬀects
on angiogenesis [2, 3]. Furthermore, recent studies have
suggested that the reverse is also true [14, 19]. For example,
chronic transgenic delivery of placental growth factor (PlGF)
to murine epidermis resulted in a signiﬁcant increase in
inﬂammatory response [19]. In addition, in a previous
study, we demonstrated that 165-amino acid form of VEGF,
VEGF165, has a direct proinﬂammatory role in the patho-
genesis of RA [14]. In this previous study, recombinant
VEGF165 was found to increase the productions of TNF-
α and IL-6 by human peripheral blood mononuclear cells
(PBMC). Moreover, the synovial ﬂuid mononuclear cells
of RA patients showed a greater response to VEGF165
stimulation than the PBMC of healthy controls (the major
cell types that responded to VEGF were monocytes). These
ﬁndings suggest that VEGF165 may act as a proinﬂammatory
mediator and as an angiogenic stimulator in RA joints, and
thus, they indicate that VEGF is an important link between
angiogenesis and the inﬂammatory process.
A number of inﬂammatory cell types participate in
maintaining a mutually activating network in RA joints,
which leads to the establishment of a self-perpetuating
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Figure 1: Scheme for the perpetuation of rheumatoid inﬂammation
by VEGF. VEGF, which is predominantly produced by rheuma-
toid synoviocytes, promotes angiogenesis and stimulates vascular
endothelial cell permeability. Newly employed macrophages pro-
duce TNF-α and IL-6 when stimulated by VEGF/Flt-1 binding
or by cell contact with activated endothelial cells. TNF-α and
IL-6, in turn, further enhance the capacity of macrophages and
synoviocytes to secrete VEGF, and thus create a self-perpetuating
cycle of inﬂammation. Meanwhile, VEGF binding to NP-1 prevents
rheumatoid synoviocytes undergoing apoptosis, which leads to
synovial hyperplasia. Hyperplastic synoviocytes, in turn, secrete
more VEGF165 and by so doing generate a positive feedback-
loop that promotes survival. Thus, the development of synovial
inﬂammation, hyperplasia, and angiogenesis in the joints of RA
patients may be regulated by a common cue, VEGF.
cycle of autoimmunity [1]. It has been documented that
VEGF165 activates endothelial cells to produce chemokines,
such as MCP-1 and IL-8 [20, 21], which may recruit
monocytes around endothelial cells in synovial membranes,
where newly employed macrophages, in addition to resident
synoviocytes, can produce TNF-α and IL-6 when stimulated
by VEGF165 (as was evidenced by our work) or via cell
contact with activated endothelial cells. TNF-α and IL-6,
in turn, further enhance the capacities of macrophages and
synoviocytes to secrete VEGF165, and stimulate endothelial
cells to induce cell-contact-mediated macrophage activation,
which generates a positive feedback-loop (Figure 1). Thus,
VEGF165 may serve as a functional bridge between endothe-
lial cells and macrophages/synoviocytes.
In RA synovium, synovial ﬁbroblasts proliferate abnor-
mally and invade local environments, and in some ways
exhibit the characteristics of tumor cells [22]. Recently, we
demonstratedthatVEGFiscruciallyrequiredforthesurvival
of rheumatoid synoviocytes [23]. In this previous study,
the ligation of recombinant VEGF165 to its receptor pre-
ventedsynoviocyteapoptosisinducedbyserumstarvationor
sodiumnitroprusside(SNP).VEGF165 rapidlytriggeredpAkt
and pERK activity, and then induced Bcl-2 expression in
rheumatoidsynoviocytes.Furthermore,VEGF165 completely
blocked SNP-induced Bcl-2 downregulation and SNP-
induced Bax translocation from the cytosol to mitochondria.
Collectively, these results suggest that VEGF functions asSeung-Ah Yoo et al. 3
an important synoviocyte survival factor in RA. As men-
tioned above, VEGF165 is present at higher levels in sera,
synovial ﬂuid, and in the inﬂamed synovial tissues of RA
patients than in those of osteoarthritis patients [13, 14].
T h e r e f o r e ,R As y n o v i o c y t e sa r em o r el i k e l yt ob es t i m u l a t e d
by VEGF165 than osteoarthritis synoviocytes, which causes
synoviocyte hyperplasia. Moreover, hyperplastic synovio-
cytes in RA joints secrete more VEGF165,a n dt h u s ,g e n e r a t e
positive feedback that promotes their survival (Figure 1).
3. EXPRESSION AND FUNCTION OF VEGF
RECEPTORS IN RA
VEGF165 exertsitsbiologicaleﬀectsbybindingwithitsrecep-
tor subtypes, that is, fms-like tyrosine kinase (Flt-1), kinase
insert domain-containing receptor (KDR) and neuropilin-1
(NP-1) [3]. Flt-1 and KDR exhibit tyrosine kinase activity,
andbothareexpressedinthemajorityofvascularendothelial
cells[8,24,25].KDRisaprimarymediatorofendothelialcell
proliferation in response to VEGF165, whereas unlike KDR,
Flt-1 is present in inﬂammatory cells, such as, macrophages
and monocytes [8, 24, 25]. Therefore, in addition to its
proangiogenic action, Flt-1 is critically involved in monocyte
activation, and in addition, it also promotes the mobilization
of myeloid progenitors from bone marrow to the blood
[8, 24, 25]. On the other hand, NP-1 has been demonstrated
to function as a nontyrosine kinase receptor for VEGF165,
and speciﬁcally, for the heparin-binding domain of VEGF165
[26, 27]. NP-1 was initially characterized as a receptor for
semaphorin 3A, which mediates the guidance of neuronal
cells [28]. In endothelial cells, NP-1 is also a coreceptor
of VEGF, and has been shown to regulate KDR-dependent
angiogenesis [26, 27]. Furthermore, NP-1 mediates the
antiapoptotic activity of VEGF165 in breast cancer cells [29].
All three of VEGF165 receptor subtypes are expressed in
RA synovium [30]. We previously demonstrated that NP-1,
rather than Flt-1 or KDR, is the major VEGF165 receptor in
RAsynoviocytes[23].NP-1wasfoundtobehighlyexpressed
in the lining layer, and on inﬁltrating leukocytes and
endothelial cells of the rheumatoid synovium. Furthermore,
the downregulation of NP-1 transcripts by short interfering
RNA caused spontaneous synoviocyte apoptosis, which was
associated with both a decrease in Bcl-2 expression and an
increase in Bax translocation to mitochondria. Therefore,
NP-1 appears to play a critical role in maintaining RA
synoviocyte survival. In addition, more recently, we found
that Flt-1 is highly expressed in the sublining of leukocytes
in RA synovium, and in monocytes from the PBMC of active
RA patients [31]. Furthermore, Flt-1 expression levels were
found to be well correlated with erythrocyte sedimentation
rates, a marker of disease activity, indicating that they reﬂect
inﬂammatory activity of RA [31]. These ﬁndings suggest
that chronic inﬂammatory milieux, such as those generated
by high concentrations of proinﬂammatory cytokines, may
upregulate Flt-1 expression on RA monocytes.
There are several potential mechanisms whereby VEGF
receptors could contribute to RA inﬂammation. First,
VEGF165 binding to KDR may lead to an increase in
angiogenesis, and thereby, the recruitment of peripheral
leukocytes to inﬂamed synovium, which diminishes the
growing burden of synoviocytes by supplying the oxygen
and nutrients required for tissue metabolism. Second, via
interaction with Flt-1, VEGF165 may directly stimulate the
productions of cytochemokines, such as TNF-α,I L - 6 ,M C P -
1, and IL-8, which are essential for the perpetuation of
chronic inﬂammation in joints. Third, NP-1 could hamper
synoviocyte apoptosis upon ligation of VEGF165, and thus,
function as a survival factor, in an autocrine or paracrine
fashion. In this manner, VEGF165 would simultaneously
regulate the developments of synovial inﬂammation, hyper-
plasia, and angiogenesis in RA joints (Figure 1).
4. BLOCKADE OF VEGF AND ITS RECEPTOR IN RA
The success of anti-VEGF antibody (Ab) treatment in cancer
patients raises the possibility of applying antiangiogenic
therapies in other diseases, such as retinopathy, RA, and
other inﬂammatory disorders. Given the pleiotropic roles
played by VEGF and its receptor in RA inﬂammation [2,
3, 8, 24], it can be postulated that anti-VEGF treatment
retards chronic synovitis in several ways, as follows: (a) it
may decrease nutrient supply to the tumor-like synovium;
(b) inhibit leukocyte adhesion and migration by decreasing
endothelial cell surface area; (c) decrease chemokine and
cytokine productions by activated endothelial cells; (d)
reduce the VEGF-induced productions of TNF-α and IL-
6 by monocytes/macrophages; (e) abrogate VEGF-induced
increases in synoviocyte survival. These diﬀerent mech-
anisms may occur independently, but it remains to be
determined which mechanism plays a dominant role in the
quenching of RA inﬂammation.
Bevacizumab, a humanized form of anti-VEGF Ab, was
the ﬁrst antiangiogenic agent approved by the FDA in the
US for the treatment of metastatic colon cancer [32], and
it was also found to be beneﬁcial for the treatment of lung
and renal cell cancer [33, 34]. Although bevacizumab is
generally well tolerated, it has some serious toxic eﬀects, for
example, hypertension, bleeding, and arterial thromboem-
bolism,whichoccurinfrequently[32–34].Currently,various
diﬀerent developmental approaches to inhibit VEGF and its
receptors are in progress. The FDA approved pegaptanib, an
anti-VEGF RNA aptamer, for the treatment of neovascular
age-related macular degeneration (AMD) [35]. Notably,
pegaptanib was found to reduce vision loss in AMD patients
by about 50% during the ﬁrst treatment year and to stabilize
vision during the second year. Other agents which target
VEGF receptors, such as, chimerized anti-KDR antibody,
VEGF-Trap, and a synthetic ribozyme of Flt-1, are also
undergoing phase I or II trials for the treatment of solid
tumors and cancer [36].
The eﬀects of VEGF and of its receptor antagonists have
also been tested in experimental models of RA. Neutralizing
Ab to VEGF was found to prevent collagen-induced arthritis
and to ameliorate established disease in mice [37], and treat-
mentwithasolubleformofFlt-1receptorsigniﬁcantlyatten-
uated the severity of murine collagen-induced arthritis [38].
Interestingly, the failure of anti-KDR Ab, but not of anti-
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indicates that anti-inﬂammation, rather than antiangiogen-
esis, may be primarily responsible for the observed eﬀects
of anti-VEGF Ab. Considering that Flt-1 tyrosine kinase
signaling promotes RA via monocyte/macrophage activation
[31, 40], the selective inhibition of Flt-1 may be eﬀective
at blocking VEGF-induced inﬂammation and angiogenesis
with minimal toxicity. However, no clinical trial on anti-
VEGF inhibitors has been undertaken in RA. Indeed, some
antirheumatic drugs with well-known clinical eﬃcacy in RA,
such as cyclosporin and anti-TNF-α Ab, have been reported
to inhibit VEGF production in RA patients [41, 42].
Through the screening of positional scanning syn-
thetic peptide libraries, we identiﬁed a soluble arginine-
richhexapeptidesequence,RRKRRR(Arg-Arg-Lys-Arg-Arg-
Arg), which binds to VEGF165, and thereby prevents it from
interacting with its receptor [14]. To increase the in vivo
stability of this peptide, we changed its peptide structure
from the L- to the D-form, and accordingly, were able to
increase its half life to more than 24 hours [14], which
makesthepeptidemoresuitablefortherapeuticapplications.
In mice, the hexapeptide RRKRRR signiﬁcantly inhibited
VEGF-induced angiogenesis, and also retarded the growth
and metastasis of colon carcinoma cells. In addition, it
strongly inhibited ongoing paw inﬂammation in arthritic
mice without apparent side eﬀects [14]. When compared
with several known VEGF antagonists, such as anti-VEGF
antibody and aptamer, RRKRRR is advantageous from the
clinical standpoint because it is a short peptide that is
easily synthesized and because it has low immunogenicity.
In a similar manner, Bae et al., also found that the novel
anti-Flt-1 hexapeptide, GNQWFI (Gly-Asn-Gln-Trp-Phe-
IIe), inhibited angiogenesis and tumor growth without side
eﬀects [43]. This peptide selectively binds to Flt-1, and
thereby, blocks the interaction between Flt-1 and VEGF
or PlGF. Investigations on the eﬀect of anti-Flt-1 peptide
GNQWFI on an experimental model of arthritis are under
way.
5. PLACENTAL GROWTH FACTOR: A NEW POTENTIAL
TARGET FOR ANTIANGIOGENIC TREATMENT
PlGF is a member of the VEGF family, which was ﬁrst
identiﬁed in placenta, but is also known to be present in
heart, lung, and joints [44]. As a speciﬁc ligand for Flt-1,
PlGF has potent angiogenic properties, and it also induces
the growth and migration of endothelial cells [24, 25].
In addition, PlGF stimulates tissue factor production and
chemotaxis in monocytes [45], and also increases TNF-
α, IL-1, IL-6, IL-8, and MCP-1 productions by normal
and/or rheumatoid monocytes [31, 46], which suggests
that it directly modulates the inﬂammatory process. PlGF
concentrations were reported to be increased in RA synovial
ﬂuids, and to induce VEGF production by mononuclear
cells [47]. Moreover, genetic ablation of PlGF prevented
the development of antibody-induced arthritis in mice [31]
suggesting the critical role of PlGF in RA inﬂammation.
PlGF exhibits functions that are distinct from those of
VEGF, in that it regulates the angiogenic switch during the
diseased state [48]. It was recently reported that neutralizing
Ab to PlGF inhibits the growth and metastasis of various
tumors, including those resistant to VEGF inhibitors, and
that it enhances the eﬃcacies of chemotherapy and that
of anti-KDR Ab [48]. Unlike anti-KDR Ab, anti-PlGF Ab
prevented the inﬁltration of angiogenic macrophages and
severe tumor hypoxia, and thus, did not switch on the
angiogenic rescue program responsible for resistance to anti-
KDR Ab [48]. Furthermore, it did not cause or enhance
anti-KDR Ab-related side eﬀects, such as, the inhibition of
placentalvasculardevelopment.Similarsuppressiveeﬀectsof
PlGF antagonist on tumor growth were observed in another
study, in which an antagonistic PlGF peptide (SHRYR-
LAIQLHASDSSSSCV) inhibited the growth and metastasis
ofhumanbreastcancerxenografts[49].Takentogether,PlGF
antagonists may prevent angiogenesis and tumor growth
without aﬀecting normal physiology, and thus, are ideal
candidates for RA treatment. We are currently investigating
whether synthetic anti-PlGF peptides inhibit the severity of
arthritis and angiogenesis.
6. CONCLUSION
We and others have demonstrated that proangiogenic fac-
tors, such as VEGF and PlGF, exert direct proinﬂammatory
[14, 19–21, 31, 40, 45, 46] and antiapoptotic eﬀects [23, 29].
In this regards, the developments of synovial inﬂammation,
hyperplasia, and angiogenesis in the joints of RA patients
mayallberegulatedbyVEGF.GiventheimportanceofVEGF
inthepathologyofRA,antiangiogenictherapies,particularly
those involving an anti-Flt-1 blocking agents, could when
administered as a monotherapy or in combination with
other biologic agents selectively ameliorate RA symptoms
and reverse its fundamental pathology. The antiangiogenic
peptides,RRKRRRandGNQWFI,introducedhererepresent
a promising development in the antiangiogenic ﬁeld. Hope-
fully, our eﬀorts will result in clinical applications.
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